Alnylam Pharmaceuticals Inc (NASDAQ: ALNY) kicked off on Tuesday, down -1.73% from the previous trading day, before settling in for the closing price of $269.95. Over the past 52 weeks, ALNY has traded in a range of $141.98-$304.39.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Over the past five-year period, the growth rate of yearbook sales for the company of the Healthcare sector was 97.61%. While this was happening, its average annual earnings per share was recorded 43.96%. With a float of $127.83 million, this company’s outstanding shares have now reached $128.98 million.
Considering the fact that the conglomerate employs 2100 people, you should pay attention to its efficiency factor. In terms of profitability, gross margin is 88.86%, operating margin of -9.34%, and the pretax margin is -15.94%.
Alnylam Pharmaceuticals Inc (ALNY) Insider Activity
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Alnylam Pharmaceuticals Inc is 0.90%, while institutional ownership is 93.70%. The most recent insider transaction that took place on Aug 20 ’24, was worth 4,200,000. In this transaction Chief Executive Officer of this company sold 15,000 shares at a rate of $280.00, taking the stock ownership to the 73,441 shares. Before that another transaction happened on Aug 20 ’24, when Company’s Officer proposed sale 15,000 for $280.00, making the entire transaction worth $4,200,000.
Alnylam Pharmaceuticals Inc (ALNY) Earnings and Forecasts
According to the Wall Street analysts, stocks earnings will be around 43.96% per share during the next fiscal year.
Alnylam Pharmaceuticals Inc (NASDAQ: ALNY) Trading Performance Indicators
Take a look at Alnylam Pharmaceuticals Inc’s (ALNY) current performance indicators. Last quarter, stock had a quick ratio of 2.69. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 16.33. Likewise, its price to free cash flow for the trailing twelve months is 2130.59.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.62, a number that is poised to hit -0.59 in the next quarter and is forecasted to reach -1.08 in one year’s time.
Technical Analysis of Alnylam Pharmaceuticals Inc (ALNY)
Compared to the last year’s volume of 0.87 million, its volume of 1.03 million showed improvement in the last five days. As of the previous 9 days, the stock’s Stochastic %D was 16.22%. Additionally, its Average True Range was 8.12.
During the past 100 days, Alnylam Pharmaceuticals Inc’s (ALNY) raw stochastic average was set at 74.29%, which indicates a significant increase from 4.03% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 29.12% in the past 14 days, which was lower than the 60.33% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $274.68, while its 200-day Moving Average is $207.10. Nevertheless, the first resistance level for the watch stands at $268.04 in the near term. At $270.80, the stock is likely to face the second major resistance level. The third major resistance level sits at $272.70. If the price goes on to break the first support level at $263.38, it is likely to go to the next support level at $261.48. Should the price break the second support level, the third support level stands at $258.72.
Alnylam Pharmaceuticals Inc (NASDAQ: ALNY) Key Stats
The company with the Market Capitalisation of 34.22 billion has total of 128,981K Shares Outstanding. Its annual sales at the moment are 1,828 M in contrast with the sum of -440,240 K annual income. Company’s last quarter sales were recorded 500,920 K and last quarter income was -111,570 K.
